United States: The Saga Of Patent Eligibility Of Business Methods Continues In SmartGene v. ABL

We reported in the last edition that the U.S. Supreme Court had agreed to consider the case of Alice Corp. Pty. Ltd. v. CLS Bank International (No. 13-298) regarding patent-eligible subject matter.  The CLS Bank decision was covered in the June 2013 edition of Full Disclosure.  Click here.  Oral arguments are scheduled for March 31, 2014, with a decision expected in the early summer.

As readers of Full Disclosure know, the en banc decision in CLS Bank International v. Alice Corp. Pty. Ltd., 717 F.3d 1269 (Fed. Cir. 2013) (en banc), failed to clarify the boundaries of patent eligibility for U.S. applicants.  If the fractured decision has any value, it is in providing interesting clues to how individual Federal Circuit judges view the question of patent eligibility.  It is hoped that when the Supreme Court opines on 35 U.S.C. § 101 this time, it will impart some predictability to the patent-eligibility analysis.

The recent decision in SmartGene, Inc. v. Advanced Biological Laboratories, SA, No. 2013-1186 (Fed. Cir. Jan. 24, 2014) (unpublished), is nonprecedential but is nevertheless interesting because the opinion was authored by Circuit Judge Richard Taranto, who joined the Federal Circuit in 2013 but did not participate in the CLS Bank decision.

Judge Taranto was joined in his opinion in SmartGene by Judges Lourie and Dyk.  Judge Lourie, joined by Judge Dyk and three other judges, wrote a concurring opinion in CLS Bank affirming the district court's holding that all claims were patent ineligible under 35 U.S.C. § 101. 

In CLS Bank, Judge Lourie evaluated Supreme Court decisions and proposed an "integrated approach" to § 101 questions based on three themes appearing in those precedents:  1) patents should not preempt fundamental tools of discovery by claiming a natural law, natural phenomenon, or abstract idea; 2) the substance of a claim is more important than its form in determining patent eligibility; and 3) courts should avoid rigid rules regarding subject-matter eligibility.  Based on these themes, Judge Lourie proposed a four-step "integrated" approach:

  1. Verify that the claim fits into one of the four statutory classes of invention (process, machine, manufacture, or composition of matter);
  2. Determine whether the claim raises § 101 abstraction concerns at all;
  3. If abstraction concerns arise, unambiguously identify the fundamental concept or abstract idea; and  
  4. After identification of the abstract idea, evaluate the remainder of the claim to determine whether it contains an "inventive concept" in the form of a "genuine human contribution" above and beyond the involved abstract idea.

Lourie then applied this approach and found all the method claims patent ineligible under § 101.  For the method claims in question, Judge Lourie found that the requirement to implement the method through a computer failed to supply an "inventive concept" because it did no more than add generic computer functionality to make the processing faster.  Judge Lourie similarly found the system claims invalid, as they only served to limit the method to a particular technological environment, which was not enough to satisfy § 101.  Judge Lourie's opinion found, at least in this case, that the method and system claims should "rise or fall" together, so that the substance of a claim controls its eligibility under § 101, rather than how artfully it was drafted.

The decision in SmartGene reveals a similar approach by Judge Taranto in holding all of the claims as patent ineligible under § 101.  Judge Taranto had no problem identifying the fundamental concept of the claims: the claims were directed to an expert system including a method and system for proposing treatment options for a patient based on a consultation of three separate databases.  The claims were written in generic terms to include "providing" patient information to a "computing device" and "generating" a ranked list of treatment options.  Judge Taranto, without formulating a specific approach, appeared to follow the same analytical framework advocated by Judge Lourie in CLS Bank.  Beginning with the question of whether SmartGene's patent contained an inventive concept, Judge Taranto noted that "[t]he claim . . . calls on a computer to do nothing that is even arguably an advance in physical implementations of routine mental information-comparison and rule-application processes.  In this context, the concern about preempting public use of certain kinds of knowledge, emphasized in Mayo, is a grave one."  SmartGene, slip op. at 9-10.  Following the Supreme Court's precedents, Judge Taranto—as did Judge Lourie in CLS Bank—found that the claims did no more than recite a "computing device," with basic functionality "to do what doctors do routinely."  Id. at 8.  Judge Taranto went on to complain that the only independent claim placed "only very broad limitations on a 'computing device'" that rendered it like a doctor's mind, and not like any specific technological implementation.  Id. at 8-9.

It is tempting to speculate what the result in CLS Bank would have been had Judge Taranto participated in the en banc decision.  It should be recalled that Judge Taranto recently joined the Federal Circuit from a private law practice, as opposed to another judicial position, so some might argue that his analyses could be more in line with Supreme Court precedent.  Ultimately, however, that would be an academic exercise, because the Supreme Court will have the next opportunity to rule on the CLS Bank matter.  However, anyone attempting to "read the tea leaves" here should remember that the Supreme Court is not predictable on this patent-eligibility issue.  One need only recall the Supreme Court's decision in Bilski v. Kappos, 561 U.S. ___, 130 S. Ct. 3218 (2010), which ushered in the current era of unpredictability following the predictable laissez-faire era following State Street Bank & Trust v. Signature Financial Group, Inc., 149 F.3d 1368 (Fed. Cir. 1998).

In order to conform to the plurality in the CLS Bank decision, patent prosecutors should draft patent specifications and claims that include both method and system claims where appropriate.  Ultimately, however, claims should be drafted to recite more than merely implementing a method through a computer, such as the ABL claims found invalid in this decision.  The claims more likely to succeed under any analysis are those that cover more than simply a process that takes place with a computer which accomplishes something that is conventionally done without a computer.  The better approach is to recite a computer-implemented method in only a portion of the claim and then recite further process steps that employ the results of the computer-implemented method to accomplish some specific, real-world task.  Of course, it is important to keep in mind the joint-infringement implications when doing so.  See a discussion on the latter here.

We invite our readership to stay tuned to Full Disclosure for analyses of CLS Bank and other Supreme Court decisions as they are handed down.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
16 Jan 2019, Conference, Washington, DC, United States

Finnegan partner Lionel Lavenue will present “The Technology Accelerates: IP Issues at the Cutting Edge” during the Embry-Riddle Aeronautical University Aviation Law & Insurance Symposium.

22 Jan 2019, Webinar, Washington, DC, United States

As part of Strafford Publications’ webinar series, Finnegan partners Shana Cyr and Mark Feldstein will provide essential updates on FDA practice and patent law relating to biologics and biosimilars.

27 Jan 2019, Other, Washington, DC, United States

Finnegan is a sponsor of the Association of Corporate Patent Counsel Winter Meeting. Finnegan partner Erika Arner will join the panel discussion “PTAB Review & Litigation.”

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions